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180 C. Castellani et al. / Journal of Cystic Fibrosis 7 (2008) 179–196AbstractIt is often challenging for the clinician interested in cystic fibrosis (CF) to interpret molecular genetic results, and to integrate them in the
diagnostic process. The limitations of genotyping technology, the choice of mutations to be tested, and the clinical context in which the test is
administered can all influence how genetic information is interpreted. This paper describes the conclusions of a consensus conference to address
the use and interpretation of CF mutation analysis in clinical settings.
Although the diagnosis of CF is usually straightforward, care needs to be exercised in the use and interpretation of genetic tests: genotype
information is not the final arbiter of a clinical diagnosis of CF or CF transmembrane conductance regulator (CFTR) protein related disorders. The
diagnosis of these conditions is primarily based on the clinical presentation, and is supported by evaluation of CFTR function (sweat testing, nasal
potential difference) and genetic analysis. None of these features are sufficient on their own to make a diagnosis of CF or CFTR-related disorders.
Broad genotype/phenotype associations are useful in epidemiological studies, but CFTR genotype does not accurately predict individual
outcome. The use of CFTR genotype for prediction of prognosis in people with CF at the time of their diagnosis is not recommended.
The importance of communication between clinicians and medical genetic laboratories is emphasized. The results of testing and their
implications should be reported in a manner understandable to the clinicians caring for CF patients.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFTR; Genetic analysis; Diagnosis; Genotype/phenotype correlation
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196A huge amount of information has been published on the
cystic fibrosis (CF) transmembrane conductance regulator
(CFTR) gene since it was identified in 1989 [1–3]. Remarkable
developments in molecular analysis techniques have resulted in
the identification of more than 1500 CFTR mutations [4], and
high sensitivity mutation panels are now available for many
populations or ethnic groups. The great strides in molecular
genetics need to be matched by equal progress in clinical
interpretation and communication. The meaning of rare mu-
tations in the diagnostic field, genotype/phenotype correlation
in the single individual, and the clinical relevance of complex
alleles and modifier genes are all issues which often raise morequestions than answers. It is often challenging for the clinician
interested in CF to interpret the molecular results, and to in-
tegrate them in the diagnostic process.
A Consensus Conference organized by the European Cystic
Fibrosis Society (www.ecfsoc.org), with the partnership of the
European Society of Human Genetics (www.eshg,org), and the
EuroGentest Network of Excellence (www.eurogentest.org),
took place in Garda, Italy, on March 23–24, 2007. Its main
purpose was to provide the CF clinician with information
relevant for the best use of CF genetic testing. Thirty experts in
cystic fibrosis and molecular genetics from Europe and North
America were involved in pre-conference consultations and in
181C. Castellani et al. / Journal of Cystic Fibrosis 7 (2008) 179–196the drafting of preliminary documents, and twenty-three
attended the meeting. The conference addressed a wide range
of issues, including CFTR analysis technical standards,
distribution of mutations, complex alleles, the use of genetic
testing for the diagnosis of cystic fibrosis, genotype/phenotype
correlation including potential impact of modifier genes, and
proper communication of the genetic test result. This document
is the result of the Consensus Conference.
1. Mutations in the CFTR gene and their analysis
1.1. Distribution of mutations
Cystic fibrosis is caused by mutations in the CFTR (ABCC7)
gene [1–3]. The most common mutation is F508del, previously
termed ΔF508, which accounts for approximately two thirds of
allCFTR alleles in patients with CF, with a decreasing prevalence
fromNorthwest to Southeast Europe [5–10]. The remaining third
of alleles are substantially heterogeneous, with fewer than 20
mutations occurring at a worldwide frequency of more than 0.1%
[4,11]. Some mutations can reach a higher frequency in certain
populations, due to a founder effect in religious, ethnic or geo-
graphical isolates [12,13] (Tables 1 and 2).
The majority of CFTR mutations have been associated with
European-derived populations [6]. There are also CFTR
mutations in non-European populations, such as African and
East Asian populations [14], but no alleles have reached the
high frequency of F508del.Table 1
Geographical distribution of the most common mutations
E60X Southern European S549N
CFTR Slavic — Eastern European G551D
R75X Southern European, US-Hispanic Q552X
394delTT Nordic — Baltic sea region R553X
G85E Southern Europe A559T
406-1GNA US-Hispanic R560T
R117H European-derived populations 1811+1.6kbANG
R117C Northern European 1898+1GNA
621+1GNT Southern European 1898+5GNT
711+1GNT French, French Canadian 2143delT
711+5GNA US-Hispanic 2183delAANG
L206W Spanish and US-Hispanic 2184delA
V232D Spanish and US-Hispanic 2789+5GNA
1078delT French Brittany Q890X
R334W Southern European, Latin American 3120+1GNA
1161delC Indian 3272–26ANG
R347P European-derived, Latin America 3659delC
R347H Turkish 3849+10kbCNT
A455E Dutch R1066C
1609delCA Spanish, US-Hispanic Y1092X (CNA)
I506T Southern European, Spanish M1101K
I507del European-derived populations 3905insT
F508del European-derived populations D1152H
1677delTA Southern European, Middle Eastern R1158X
1717–GNA European-derived populations R1162X
V520F Irish S1251N
G542X Southern European, Mediterranean W1282X
S549R(TNG) Middle Eastern N1303K
Legend: these alleles occur with a frequency superior to 0.1% in selected population
derived” indicates presence in Europe, and due to immigration also in America, Au
References: [4,15,11,30,144–150].Overviews of the distribution of CFTR mutations causing CF
have been produced by WHO [11] and Bobadilla et al. [15]. In
approximately two thirds of all instances the entire CFTR coding
region has been analysed, and therefore in these reports some
mutations which were easier to screen for are over-represented,
compared to those which are more difficult to determine from the
technical point of view. The reviews do not contain data on intra-
CFTR rearrangements, and have limited information onmutations
occurring in non-European-derived populations. A project for
updating the previous WHO review is currently in progress.
To date more than 1500 sequence alterations have been
identified in the CFTR gene and their listing is continuously
updated within the Cystic Fibrosis Genetic Analysis Consortium
(CFGAC) database [4]. In the databasemissensemutations account
for 42%, frameshift for 15%, splicing for 12%, nonsense for around
10%, inframe insertions/deletions for 2%, large insertions/deletions
for 3%, promoter mutations for 0.5%, and sequence variations
which are not predicted to be disease-causing for 15% of all alleles.
De novo mutations and uniparental disomy of chromosome 7
bearing a mutated CFTR gene are exceptional events.
Conclusion: CFTR mutations vary in their fre-
quencyand distribution in different populations. Very
few mutations have a worldwide frequency above
0.1%, but some can reach high prevalence in
selected populations.Indian
United Kingdom, Central Europe
Southern European, Italian
Central European
African-American
Northern Irish
Spanish, US-Hispanic
United Kingdom, Central Europe
East Asian populations
Slavic — Eastern European
Southern Europe, Middle Eastern, Iranian, Latin American
European-derived populations
European-derived populations
Southern European
African, Arabian, African-American, Southern Europe
European-derived populations
Scandinavian
Ashkenazi-Jewish, Southern European, Middle Eastern, Iranian, Indian
Southern European
Southern European
US-Hutterite
Swiss
European-derived populations
Southern European
Italian, Amerindian, Latin America
European-derived populations
Ashkenazi-Jewish, Middle Eastern
Southern European, Middle Eastern
s. Limitations due to small numbers are discussed, elsewhere [144]; “European-
stralia, etc.
Table 2
CFTR mutations in selected populations
Regional European Middle Eastern
2184insA Central European I1234V Bahrain
I336K Central European Q359K/T360K Georgian-
Jewish
574delA Central European, French 3130delA Iranian
4374+1GNT Eastern European H139L Saudi
S1196X Estonian, Finish,
Russian
1548delG Saudi
3732delA Estonian, Finish,
Russian
S466X Turkish, Greek,
Iranian, Indian
W846X1 French Brittany Y569D UK-Pakistani
Q220X French, Bulgarian
S945L French, Central European East Asian
L1065P French, Italian 1898+5GNT Chinese, Thai
L1077P French, Italian 3121-2 ANG Japanese
4016insT French, Italian, Swiss K166E Korean
Y122X French, Reunion
Island
2711delT French, Spanish Hispanic
S1235R French, Spanish Q98R
1525–1GNA German (Thuringia) 663delT
L346P Greek Cypriot H199Y
E822X Greek, Turkish P205S
R352Q Irish, Italian 935delA
852del22 Italian (Apulia) 1288insTA
T338I Italian (Sardinia) 2055del9NA
A561E Portuguese 2105del13insAGAAA
45TATNG Northern Balkans 3171delC
P67L Scottish 3199del6
1154insTC Southern European 3876delA
4005+1GNA Southern European
405+1GNA Southern European US African-American
D110H Southern European 405+3ANC
E585X Southern European 444delA
L558S Southern European F311del
Q493X Southern European G330X
R1066H Southern European G480C
G1244E Southern European A559T
G178R Southern European 2307insA
E92K Southern European,
Turkish
3196del54
R1070Q Southern European,
Turkish
3791delC
W1089X(TAG) Southern European,
Turkish
S1255X
W1204X Southern European,
US-Hispanic
D1270N
1812-1GNA Southern European,
US-Hispanic
S492F Southern European,
US-Hispanic Native American
K710X Southern French,
Spanish
D648V
V232D Spanish L1093P
712–1GNT Spanish R1162X
A1006E Spanish
Q890X Spanish, US- Hispanic References
[11,15,30,144–150]2869insG Spanish-Catalan
2043delG Turkish, Greek
CF-causing and CFTR-related disorders associated mutations are included.
Some mutations may be found in more than one column.
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CFTR genetic analysis panels should have a mutation
detection rate superior to 95%, but the heterogeneity of CFTR
mutations in various populations makes this goal extremely
challenging using the current molecular genetic techniques.
Every effort should be made to determine the frequency of
specific CF mutations within the target population and to pro-
vide testing with reasonably high sensitivity levels. Labora-
tories that service a particular ethnic population should consider
including ethnic-specific mutations into their panel [16].
Different testing panels might be employed for identification
of CFTR mutations in patients diagnosed with CF, as opposed
to relatives of CF patients, where the family specific mutation
should be tested first. An extended mutation panel may be
appropriate for certain diagnostic testing purposes, but it is not
currently recommended for routine carrier screening [17].
Evidence has accumulated that a group of intragenic rear-
rangements (i.e. large deletions and to lesser a extent insertions)
[18] account for about 1–3% of all CFTR mutations. The large
deletions and/or insertions so far detected are mainly localised
around CFTR exons 2–3 and 17b. These deletions are rare, with
the exception of CFTRdele2,3 (21kb), which accounts for 6% of
all CF alleles in Slavic populations [19]. These alleles are
optimally examined either by Multiplex Ligation-dependent
Probe Amplification (MLPA) or Quantitative Fluorescent
Multiplex PCR [20,21].
Mutation scanning approaches (DGGE, DHPLC, HRMCA)
have been designed to explore the gene exon by exon for
abnormalities, most often as a second-step analysis after screen-
ing for frequent mutations. Sequencing is then used to char-
acterize the abnormal pattern. Scanning techniques are still
widely used although it has become feasible to sequence the
entire CFTR gene in the diagnostic setting [22]. However,
mutation scanning techniques result in a considerable risk of
missing mutations, in particular homozygous alleles, and even
with complete gene sequencing a small risk remains. Sequen-
cing is also used when the mutation under investigation cannot
be detected by alternative direct techniques, e.g. after the
population specific panel has been exhausted and/or mutations
that occur at a frequency of at least 0.5% have been excluded.
Once a rare missense mutation has been identified, caution has
to be exercised in order not to over interpret its significance to
disease causation.
The combined use of all these techniques cannot guarantee to
detect both mutated alleles in all patients with CF [18,23–25],
1–5% of CF alleles remaining undetermined. Currently used
CFTRmutation analysis protocols are not capable of identifying
CFTR regulatory mutations located in sites distant from the
gene or embedded in the genes' non-coding regions [26]. At
present, research is ongoing to identify eventual mutations in
potential regulatory elements, including the gene promoter [27],
highly conserved DNA segments, DNAse hypersensitive sites,
and/or distant regulatory elements [28]. Mutations of this type
are expected to abolish or reduce production of functional
CFTR [29], and could be associated with a clinical spectrum
from classic CF to CFTR-related disorders.
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CFTR mutations have been identified, segregation analysis of
CFTR polymorphic non pathogenic markers may provide fur-
ther helpful information for identifying disease genes. Multiple
informative markers are available both in the CFTR gene and
flanking the gene. It is recommended that more than one marker
be included in the analysis, and the diagnosis of CF in the index
case should be clearly defined. Ideally, one should use intra-
genic and extragenic markers, since the risk for unidentified
recombination between marker and mutation is lower if flank-
ing markers are concordant. Analysis of variable markers at loci
on different chromosomes should also be performed when
offering prenatal diagnosis as an added safeguard for maternal
contamination.
Conclusion: Current analytic methods to detect
mutations in the CFTR gene range from panels
containing the most common disease-causing
alleles to extensive scanning/sequencing protocols
that enable the detection of novel mutations and to
methods to identify large rearrangements. How-
ever, even the most extensive CFTR mutation
screening tests fail to detect all CF alleles in most
CF populations.1.3. Quality control
DNA-based analyses are carried out in a variety of settings,
including academic research laboratories, clinical molecular
genetics laboratories, and private laboratories. As commercial
kits are only available for limited number of mutations and are
expensive, many laboratories, especially in less developed
countries, use their own in-house test methodologies, which are
usually not amenable to automation and rigorous standardiza-
tion. These approaches have a higher risk of producing invalid
results.
In Southern European populations, which show high mole-
cular heterogeneity, commercial mutation panels cover only
50–75% of alleles and scanning/sequencing techniques may be
used in genetic analysis performed for CF diagnostic purposes
[8,30].
The diagnostic services should be organized at two levels:
Level 1 (i.e. “local testing”) where only frequent mutations are
tested, ideally reaching 75–85% detection rate of CF-causing
alleles in patients with a clearly defined phenotype, and Level 2,
represented by a limited number of national and/or regional
expert laboratories that test for less frequent mutations using
more sophisticated technologies in order to achieve the highest
possible mutation detection rate [31–33]. Each laboratory must
show that its tests can consistently deliver the correct genotype
under normal working conditions. In order to evaluate the
quality of genetic testing for cystic fibrosis, a Cystic Fibrosis
External Quality Assessment (EQA) scheme has been set up[34]. EQA schemes seek to educate participants, so that they can
achieve high quality standards, and regular participation in
EQA is a vital part of the quality assurance process and a
requirement for laboratory accreditation. Different sources of
errors include administration errors, technical errors or mis-
interpretation of technically correct results. The use of a com-
mercial kit alone does not ensure high accuracy of mutation
analysis, which stresses the importance of validating all genetic
tests in the laboratory, and the need for laboratory networks at
regional or national levels.
Clinicians should be aware that the quality of the test is
associated with diagnostic validation procedures and contin-
uous improvement of laboratory quality using the latest ISO
norms or National Molecular Genetic Agreements. The minimal
standard for countries without a national agreement system is
“certification” (e.g. ISO 9001), while optimally the laboratory
should be accredited according to ISO 17025 or 15189, which
assures sustained and continuous improvement of the standards
of laboratory testing. The EuroGentest FP6 Network of Ex-
cellence (www.eurogentest.org), together with Orphanet (www.
orpha.net), is launching a Quality Assurance database where the
referring clinicians will be able to select a laboratory that is
accredited or certified.
Recommendation: Referring clinicians should
use molecular genetic diagnostic services from
certified and/or accredited laboratories.2. The role of genetic analysis for establishing the diagnosis
of CF
The diagnosis of CF is based on a consistent phenotype plus
evidence of CFTR channel dysfunction (abnormal sweat chlo-
ride concentration or nasal potential difference), or identifica-
tion of two CF-disease causing mutation in trans [35]. The
sweat test with chloride determination is still the gold standard
for confirming a CF diagnosis [35,36]. In the majority of cases
the diagnosis of CF is clear and easily made: the clinical features
are typical, and the abnormal sweat chloride values support the
clinical diagnosis. In such situations, genetic analysis is not
strictly necessary, although it may be useful to confirm the
diagnosis, and to enable carrier testing and prenatal diagnosis
within the family. In a smaller fraction of patients, particularly
those that carry one or more mutations that confer exocrine
pancreatic sufficiency, sweat chloride concentrations may be
within the reference range for unaffected controls. In some of
these patients, provided they have consistent clinical features,
genetic analysis may support a diagnosis of CF [35–37].
From a formal genetic perspective, the term “mutation” is
defined as a molecular alteration in the DNA sequence of a
gene. Accordingly, this definition makes no assumptions con-
cerning the potential effect of a mutation on the expression or
function of the protein product. Thus, in terms of clinical
Table 3
Examples of CFTR mutations with regard to their clinical consequences
Mutation group Examples
A. CF-causing F508del, R553X, R1162X, R1158X, 2184delA,
2184insA, 3120+1GNA, I507del, 1677delTA,
G542X, G551D, W1282X, N1303K,
621+1GNT, 1717-1GNA, A455E, R560T, G85E,
R334W, R347P, 711+1GNT, 711+3ANG⁎,
1898+1GNA, S549N, 3849+10kbCNT, E822X,
1078delT, 2789+5GNA, 3659delC, R117H-T5
(⁎),R117H-T7 (⁎), D1152H (⁎), L206W (⁎),
TG13-T5 (⁎)
B. CFTR-related
disorders associated
R117H-T7(⁎), TG12-T5(⁎), R117H-T5 (⁎),
D1152H (⁎), TG13-T5 (⁎), S997F, R297Q⁎,
L997F, M952I, D565G⁎, G576A⁎, TG11-T5⁎⁎,
R668C-G576A-D443Y, R74W-D1270N
C. No clinical
consequences
I148T, R75Q, 875+40A/G, M470V, E528E,
T854T, P1290P, 2752-15G/C, I807M, I521F,
F508C, I506V, TG11-T5⁎⁎
D. Unknown or uncertain
clinical relevance
Mainly missense mutations⁎⁎⁎
(⁎) mutations which may belong either to Group A or to Group B.
(⁎⁎) mutations which may belong either to Group B or to Group C.
(⁎⁎⁎) certain common sequence (missense) variants with subclinical molecular
consequences (e.g. M470V) may co-segregate on the same chromosome and
exert more potent, cumulative phenotypic effect. Such polyvariant haplotypes
could be potentially disease causing [56].
Only a fraction of mutation and patients have been characterized in detail, and,
with the exception of frequent mutations, only limited sample numbers have
been available for the study of most mutations. Data shown here have to be
interpreted with caution.
Table 4
Splicing mutations generating both correctly and aberrantly spliced transcripts in
CF patients
Mutation Affected
exon/intron
Correctly spliced
transcripts (%)
Reference
3849+10kbC-NT Intron 19 1–50 [43]
[151]
IVS8-T5 Intron 8 6–37 [50]
[61]
2789+5GNA Intron 14b 4 [152]
3272–26ANG Intron 17a 5 [47]
1811+1.6kbANG Intron 11 1–3 [153]
621+3ANG Intron 4 ~50% (semiquantitative) [154]
711+3ANG Intron 5 ~70% (semiquantitative) [154]
2751+2TNA Intron 14a 30–50% (semiquantitative) [154]
296+1GNA Intron 2 ~30% (semiquantitative) [154]
D565G Exon 12 15–30% [28]
G576A Exon 12 22% [28]
D579Y Exon 12 N75%? (semiquantitative) Al-Baba, pers.
comm. 2007
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beneficial. Another much used term, polymorphism, is defined
as a DNA sequence alteration which has a frequency of at least
1% in the general population. Given their high frequency,
polymorphisms were previously thought to have no clinical
consequences. This assumption is clearly incorrect. Several
polymorphisms in CFTR are known to influence disease
severity in subjects with CF and CFTR-related disorders
[38,39]. Furthermore, polymorphisms in other genes, termed
modifier genes, clearly contribute to the severity of CF disease.
CFTRmutations may be clustered into four groups according
to their predicted clinical consequences:
A. Mutations that cause CF disease
B. Mutations that result in a CFTR-related disorder
C. Mutations with no known clinical consequence
D. Mutations of unproven or uncertain clinical relevance.
There is some overlapping of groups A and B, as some
mutations may sometimes be detected in association with pan-
creatic sufficient CF, some other times with CFTR-related,
mono-symptomatic disorders. Individuals carrying mutations
like D1152H together with a CF-causing mutation like F508del
may show a clinical spectrum ranging from CBAVD to CF with
sufficient pancreatic function but fully expressed lung disease.
Factors such as the age related progression of the disease, the
environment, and modifier genes, all play a role in the clinical
heterogeneity of patients carrying these “borderline” mutations.Table 3 lists some CFTR mutations with regard to their clinical
consequences.
Conclusion: Mutation analysis may be used for
making a diagnosis of CF in individuals with a con-
sistent clinical picture.CFTRmutationsmay:A. cause
CF; B. be associated with CFTR-related disorders; C.
have no clinical consequences; D. have unknown or
uncertain clinical relevance.2.1. Mutations that cause CF
Ex vivo functional evaluation of the CFTR protein can
help to predict the disease-causing implications of a sequence
variation. In vivo assessment of CFTR-mediated chloride trans-
port can be indirectly assessed by sweat chloride concentra-
tions, nasal potential difference or rectal biopsy measurement
of chloride transport.
Empiric evidence for the most common mutations and/or
a clear pathogenic molecular mechanism for insertions, dele-
tions, and nonsense mutations, strongly indicate that such mu-
tations belong to the CF-causing group.
Splicing mutations that completely abolish exon recognition
(such as 621 + 1G N T, 711 + 1 G N T and 1525-1G N A) give
complete absence of correctly spliced transcripts, and thus
belong to the CF-causing group [40,41]. Splicing mutations that
still result in a fraction of correctly spliced transcripts, together
with aberrantly spliced transcripts, may belong to the CF-caus-
ing or CFTR-related disorders associated group (e.g. 3849+
10kbCNT, 2789+5GNA, 3272-26ANG, IVS8-T5) [42–44].
Patients carrying these mutations often have a relatively mild
phenotype, yet with variable disease expression, from minimal
lung disease, pancreatic sufficiency and male fertility to a
relative severe disease in all the involved organs [45,46]. This
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quantity of correctly spliced transcripts, i.e. lower levels are
associated with a severe disease, while higher levels are asso-
ciated with a milder phenotype (Table 4).
The quantity of correctly spliced transcripts may also dif-
fer among various organs of the same patient, contributing to
differential organ disease severity [28,47–52]. Several groups
studied the IVS8-T5 allele in the respiratory epithelium and
epidydimis [49,50], showing that in CBAVD males the level of
correctly spliced transcripts is lower in the epidydimis than in
the respiratory epithelium (10–24% versus 26–37%), whereas
in an infertile male CF patient with a severe lung disease the
level of correctly spliced transcripts was low in both tissues. A
similar correlation was also shown for the 3849 + 10kbC N T
mutation [51].
The extent of abnormal splicing in a patient is not determined
in routine diagnostics tests, because cells expressing CFTR are
difficult to obtain in sufficient quantities, and their analysis is
very laborious. Besides, the percentage of correctly spliced
transcripts in patients with mild disease varies within a large
range of 4% to 50%, whereas severe disease is caused by lower
levels of correct transcripts.
The clinical role of missense mutations is extremely difficult
to assess. The identification of a missense mutation in a single
family/individual makes it impossible to determine with cer-
tainty whether it has any consequential effect. Several missense
mutations are commonly seen in the general population but also,
more frequently, in patients with CFTR-associated disorders.
For a small fraction of mutations, the functional consequences
have been determined in research projects, and these findings
can be used to predict the most likely consequences of such a
mutation.
These difficulties account for the lack of a clearly established
or substantiated knowledge of the pathogenic potential of the
majority of the known CFTR mutations. However, a general
acknowledgement [36] has been agreed upon that a sequence
variation may be predicted to cause CF if:
- it causes a change in the amino acid sequence that severely
affects CFTR synthesis and/or function
- it introduces a premature termination signal (insertion, de-
letion or nonsense mutation)
- it alters the invariant nucleotide of intron splice sites.
Other criteria can be used to asses the pathogenic potential,
but they provide a lower degree of certainty. Some of them
include:
- the sequence variation causes a novel amino acid sequence
that does not occur in the normal CFTR gene from at least
100 carriers of CF mutations from the patients ethnic group
- the sequence variation is detected in a set number of un-
related individuals with CF
- the sequence variant changes a highly evolutionarily con-
served amino acid residue
- the sequence variation creates a novel/cryptic splice site
- similar sequence variations are found in other ABC genes.Indirect evidence that a CFTR sequence variations does not
cause CF is:
- the other allele is carrying a well know CF-causing mutation
in a clearly asymptomatic individual
- a silent exonic sequence variation, without a priori splicing
modification
- an intronic sequence variation outside the known consensus
sites and which does not create a splicing site
- frequency in the general population equal to or above 0.4%
[53].
Conclusion: Mutation analysis is not the answer
to every diagnostic dilemma: its limitations and role
must be understood by the clinician, who has to
interpret and use it in the context of the clinical
setting. The majority of the CFTR mutations have
not been functionally characterized, and for most
the pathogenic potential is not clear.2.2. Complex alleles
Genetic analysis may result in the identification of a common
CF-causing mutation and a rare CFTRmutation or of two CFTR
mutations. Under these circumstances, segregation analysis
should be performed in the family of the patient. If the two
mutations are on the same parental CFTR gene, it is said they are
in cis; if each mutation is on a different parental CFTR gene, it is
said they are in trans. When the two mutations are in cis, CF
may not be confirmed, and the search of another allelic mutation,
located in trans of the other two, should be continued. CFTR
genes that carry at least two functional DNA alterations in cis,
are called “complex alleles”. The best understood complex
alleles of the CFTR gene are the associations of intron 8 (IVS-8)
variants TG13-T5, TG12-T5 and TG11-T5, of R117H-T5 and
R117H-T7, and of mutations I148T and 3199del6.
A. TG13-T5, TG12-T5 and TG11-T5 variants
Two polymorphic tracts are found in front of exon 9, a T(n)
tract and TG(n) tract. At the Tn locus, three common alleles
may be detected: T5, T7 and T9, and a much rarer T3 [54]
(respectively a stretch of 5, 7, 9 and 3 T-residues). A T5 CFTR
allele can be associated with TG11, TG12, TG13, and, excep-
tionally, TG15 (respectively 11, 12, 13, and 15 TG repeats) [55].
The number of T and/or TG repeats within these polymorphic
tracts affect the extent of correct splicing of exon 9: low
numbers of T-residues and high numbers of TG repeats give rise
to less efficient splicing [42,56,57]. Transcripts that lack exon 9
sequences fail to mature [58,59].
About 5% of the CFTR genes in the general Caucasian
population carry the T5 allele [60]. In most T5 CFTR genes, the
number of TG repeats found in cis determines whether the
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fall above or below the critical level for normal CFTR function
[56,38]. A TG12-T5 or TG13-T5 CFTR gene found in com-
pound heterozygosity with a CF-causing mutation, or possibly
even in homozygosity, will in general result in a CFTR-related
disorder, such as Congenital Bilateral Absence of the Vas
Deferens (CBAVD) or chronic idiopathic pancreatitis. Some
CBAVD patients may develop mild lung symptoms. In
exceptional cases, TG12-T5 and TG13-T5, may cause a mild
form of CF [61]. A TG11-T5 CFTR gene is highly unlikely to
cause disease. Approximately 90% of the T5 CFTR genes
found in CBAVD patients associate with TG12 or TG13, while
about 10% associate with TG11 [56,38,62].
B. R117H-T5 and R117H-T7 complex alleles
R117H is a relatively frequent mutation in CF patients
worldwide [11]. R117H can be in cis with either T5 or T7 [63].
R117H-T5 will result in less functional CFTR than R117H-T7
[42]. When found in compound heterozygosity with a CF-
causing mutation, or possibly even in homozygosity, R117H-T5
generally results in pancreatic sufficient CF, while R117H-T7
may result in a mild form of CF, obstructive azoospermia, or no
disease at all.
In newborn screening programs, up to 7% of the newborns
who have an elevated immunoreactive trypsinogen test and two
mutations are compound heterozygous for R117H-T7 and a CF-
causing CFTR mutation [64]. In their first years of life, these
children have shown no major signs of CF, although it cannot be
excluded that they may develop manifestations of CF disease in
adulthood [65].
C. I148T-3199del6 complex alleles
Soon after the identification of the CFTR gene, the detection
of mutations was time-consuming and expensive. If a missense
mutation which involved a highly evolutionarily conserved
amino acid, and which was not found in a set of control indi-
viduals, was identified in a CF patient, it was defined as a CF-
causing mutation. In most instances, such a CFTR allele was
then not further investigated, since the underlying mutation was
assumed to have been identified. Besides, there was a general
consensus that only a limited number of mutations would be
found in CF patients.
On these grounds, the I148T sequence variation [66] was
initially classified as a frequent CF-causing CFTR mutation.
The American College of Medical Genetics (ACMG)
therefore included the I148T mutation in its mutation panel
of 25 mutations that were recommended to be screened in
CF carrier testing [67]. Since then, however, it has been
found that I148T is a neutral polymorphism [68–70]. A
second mutation, 3199del6 is the underlying mutation in cis
in most I148T CFTR genes of CF patients. Since only 1% of
all I148T CFTR genes in the general Caucasian population
carry the 3199del6 mutation, I148T should not be routinely
screened for. In 2004, ACMG recommended to remove
I148T from the mutation panel [17].Conclusion: A TG13-T5 or TG12-T5 CFTR gene
found in compound heterozygosity with a CF-
causingmutationmay result in CFTR-related disease,
or even in a mild form of CF. ATG11-T5 CFTR gene is
highly unlikely to cause disease.
When R117H is detected, the T5 or T7 status
should also be established. In compound hetero-
zygosity with a CF-causing mutation, or in homo-
zygosity, R117H-T5 generally results in pancreatic
sufficient CF, while R117H-T7 may result in a mild
form of CF, CBAVD, or no disease at all.
I148T alone is a neutral polymorphism and
does not cause CF disease.
2.3. Non-CFTR genes causing CF-like clinical syndrome
Not in every patient with CF can a mutation be identified on
bothCFTR genes. This happens in 1–1.5% of theCFTR alleles of
patients with fully expressed disease fromNorthern Europe and in
an even higher proportion ofCFTR alleles from Southern Europe
[11]. As mentioned before, the inability to detect these mutations
may be partially explained by the fact that the currently most
advancedCFTR genetic tests study only the coding region and the
adjacent exon/intron junctions. Mutations located in the intronic
and promoter regions as well as distant regulatory sequences are
not routinely screened for, and may therefore be missed.
However, there is emerging evidence that genes other than
CFTR may cause a disease clinically indistinguishable from
CF. In a German family, no mutation could be identified in both
CFTR genes of a CF patient, and his sister, who had inherited the
same CFTR genes from their parents, was not affected [71]. In
two American families, each of them having two affected sibs,
no mutations could be found on both CFTR genes, while both
sibs did not inherit the same parental CFTR genes [25].
CF is characterized not only by defective chloride secretion,
but also by increased sodium absorption in the airways. Sodium
transport is mediated through the amiloride sensitive epithelial
sodium channel, ENaC, which is made of the 3 subunits
SCNN1A, SCNN1B and SCNN1G. Over expression of
SCNN1B results in increased airway epithelial sodium absorp-
tion and CF-like lung disease in mice [72]. There is evidence
that mutations in SCNN1B may cause CF-like disease in a small
fraction (about 10%) of CF patients in whom a CFTR mutation
cannot be found on both CFTR genes [73]. The genetic factor(s)
causing CF-like disease in the other patients remains unknown.Conclusion: There is some evidence that other
genes may cause CF-like disease in a small fraction
of patients. These findings are too preliminary to be
used in a clinical context.
3. Genetic analysis for outcome prediction
CF is characterized by a wide range of clinical expression. If
not detected by neonatal screening, patients are diagnosed with
various modes of presentation, involving a variety of CF-
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addition, there is considerable variability in the severity and rate
of disease progression of the involved organs. Although the
majority of CF patients are diagnosed in the first year of life
with signs and symptoms of malnutrition, pancreatic insuffi-
ciency (PI) or typical lung disease, an increasing number of
patients have been diagnosed in adolescence or adulthood.
The heterogeneous range of phenotypes can be attributed to
various factors, such as CFTR genotype, modifier genes and
environmental factors, including the beneficial and harmful
effects of treatment [74]. The beneficial contribution of therapy
is exemplified by the progressive improvement in survival of
CF patients over the last 5 decades, which can be attributed
entirely to changes in approach to therapy of patients, including
provision of pancreatic enzymes, intensive nutritional support,
and antibiotics for pulmonary infections, aggressive physiother-
apy and multidisciplinary care [75]. Although these environ-
mental modifiers have had a profound effect upon the survival
of CF patients as a whole, considerable variation in outcome
continues to exist among individual patients, even among those
with the same CFTR genotype receiving similar levels of care.
There is substantial interest in the influence of the CFTR
genotype on phenotype. The relative impact of CFTR genotype
on clinical phenotype is organ specific, with the vas deferens
being most sensitive to a small reduction in CFTR function and
the lung less influenced [76]. The initial studies of genotype and
phenotype relationships focused on patients carrying F508del.
Patients homozygous for F508del usually have more pro-
nounced clinical manifestations compared to compound hetero-
zygotes and genotypes without F508del [77–80], although
these differences are highly variable [77,81,82]. Patients homo-
zygous for the F508del mutation have an earlier diagnosis ofTable 5
Classes of CFTR Mutations
Class of
mutation
Molecular defect of
the CFTR protein
Type of mutation Functional
consequence
I Defective synthesis Nonsense CFTR function
abolishedFrameshift
Splice junction
II Defective
processing and
maturation
Missense CFTR function
abolished
III Defective
regulation
Missense CFTR function
abolished
IV Defective
conductance
Missense Residual expression
and function
V Reduced
function/synthesis
Splicing defects
Missense mutations
(e.g. A455E)
Residual expression
and function
Examples of mutations classified as class I, II or III:
G542X, R553X, W1282X, R1162X, E822X, 621+1GNT, 1717-1GNA,
1078delT, 711+1GNT, 1525-1GNA, 2751+2TNA, 296+1GNC, 1717-
9TNC, 3659delC, F508del, I507del, N1303K, S549N, G551D, R560T,
S549I, S549R, S945L, H1054D, G1061R, L1065P, R1066C, R1066M,
L1077P, H1085R, V520F, R560S, Y569D.
Examples of mutations classified as class IV or V:
R117H, R334W, R347P, 3849+10kbCNT, 2789+5GNA, A455E, R117C,
R117P, R117L, D1152H, L88S, G91R, E92K, Q98R, P205S, 3272-26ANG,
IVS8-T5, D565G, G576A, 4006-1GNA, 621+3ANG, 711+3ANG.disease, higher sweat Cl− levels, younger current age and are
more likely to be pancreatic insufficient.
In order to collect adequate numbers of patients for com-
parative analyses, genotype–phenotype correlations have been
undertaken using the CFTR mutations classification of five
classes, which is shown in Table 5 [83–85]. In general, patients
homozygous for class I–III mutations exhibit a phenotype asso-
ciated with pancreatic insufficiency, higher frequency of me-
conium ileus, premature mortality, earlier and more severe
deterioration of lung function, higher incidence of malnutrition
and severe liver disease. Class IV–V mutations are usually asso-
ciated with milder lung disease, older age at death, pancreatic
sufficiency [77,86,44]. Class IV–V mutations are phenotypically
dominant when occurring in combination with class I–III muta-
tions. As discussed in more detail below, these differences are not
fully explained by clinical measures of lung function, nutrition,
and pancreatic insufficiency, suggesting that the CFTR genotype
is an independent predictor of survival.
These broad genotype/phenotype associations are useful in
epidemiological studies which relate the severity of CF to the class
of mutations. While this functional classification of CFTR muta-
tions is widely used in the scientific literature to establish statistical
associations, it was not developed as a clinical tool for individual
prognostic predictions. Since there is considerable variability in
phenotype, even with patients carrying the same genotype, the use
of genotype to make statements of prognosis is not recommended.
First, the number ofmutations so far identified in theCFTR gene is
exceedingly high, and most of them are too rare to draw statistical
conclusions regarding phenotype. Second, only a fraction of them
have been characterized according to their functional conse-
quences. Third, a number of CFTR mutations have several
functional consequences, and cannot be assigned to one particular
class. Finally, patients homozygous for mutations, like F508del,
classically associated with a severe and complete form of CF,
exhibit an extremely wide range of severity of pulmonary disease
mild disease. Such clinical variability is likely to be even more
pronounced by clustering together different mutations belonging
to the same class.Conclusion: The CF phenotype is affected by the
CFTR genotype as well as by other genetic and en-
vironmental factors. When patients who are homo-
zygous, or compound heterozygous for a class I–III
CFTRmutation, are compared to patients who carry
at least one class IV–V CFTR mutation, the latter
group tends to have less severe disease. The catego-
rization of CFTR mutations in five classes is a re-
search tool, and is not predictive of clinical outcome
in individual patients. Thus, CFTR genotype/pheno-
type correlations may be useful at a population level
to determine associations, but should not be used to
indicate prognosis in individual patients.3.1. CF genotype and pancreatic status
Pancreatic insufficiency (PI) and sufficiency (PS) are clinical
terms describing the degree of pancreatic function and are
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sufficiency occurs when less than 2% of the exocrine pancreas
is functioning, which gives rise to fat malabsorption, thereby
requiring exogenous pancreatic enzyme replacement therapy.
Pancreatic sufficiency means that the residual exocrine pan-
creatic function is sufficiently preserved to allow normal fat
absorption and therefore enzyme replacement is not required.
Pancreatic status is measured by fecal fat, fecal elastase, serum
trypsinogen, or quantitative studies of the pancreas. The pres-
ence of clinical symptoms suggestive of malabsorption is not an
accurate way to determine pancreatic status [87].
There is a strong relationship between CF genotype and
pancreatic status: Class I–III mutations (also called “severe”
mutations) are associated with pancreatic insufficiency, andTable 6
Main CFTR mutations as related to pancreatic status
Usually PI associated mutations Usually PS associated mutations
F508del R117H
G542X R347P⁎⁎
G551D 3849+10kbCNT
N1303K A455E
W1282X R334W⁎⁎
R553X G178R
621+1GNT R352Q
1717-1GNA R117C
R1162X 3272-26ANG
I507del 711+3ANG
394delTT D110H
G85E⁎ D565G
R560T G576A
1078delT D1152H
3659delC L206W
1898+1GNT V232D
711+1GNT D1270N
2183AANG
3905insT
S549N
2184delA
Y122X
1898+5GNT
3120+1GNA
E822X
2751+2TNA
296+1GNC
R1070Q-S466X⁎
R1158X
W496X
2789+5GNA⁎
2184insA
1811+1.6kbANG
1898+1GNA
2143delT
1811+1,6kbANG
R1066C
Q890X
2869insG
K710X
1609delCA
PS/PI classification is based on an apparent consensus from literature or from
unpublished reports.
⁎may also be associated with PS.
⁎⁎may also be associated with PI.Class IV and V mutations (also called “mild” mutations) with
pancreatic sufficiency. A class I–III allele, if paired with another
class I–III allele, is associated with PI but the presence of one
class IV or V allele is usually enough to confer PS [88].
These correlations are not absolute, and some mutations may
be associated with either pancreatic sufficiency or insufficiency.
Patients identified by neonatal screening and who carry class I–
III mutations on both alleles may be pancreatic sufficient at
diagnosis, but develop PI within the first 1–2years of life [89].
Later in life, although most patients appear to maintain PS for
many decades, a small percentage of patients with pancreatic
sufficiency appear to develop insufficient digestive function as
they grow older. Recurrent acute pancreatitis or chronic
pancreatitis is seen in 20% of PS patients, and PI can result
from the repeated inflammatory parenchymal damage [90].
Table 6 lists the pancreatic status associated with the most
frequent CFTR mutations.
Conclusion: Patients who carry class I–III muta-
tions on both alleles are likely to be pancreatic
insufficient, whereas those carrying at least one
class IV–V CFTR mutation has a high probability of
being pancreas sufficient. Pancreatic sufficient
patients tend to have better nutritional status, but
are also at significant risk for developing
pancreatitis.
3.2. CF genotype and pulmonary involvement
The lung has the greatest variability of disease severity of all
organs involved in CF. Modifier genes, environmental and treat-
ment factors all play important roles [78,80,82,88,79,81,91–94].
CF twin and siblings studies show that the proportion of CF
variance that can be attributed to genetic factors, i.e. the her-
itability, ranges from 0.6 to 0.8 [95,96]. This indicates that
modifier genes are primarily responsible for variation in pul-
monary disease severity in patients living in the same household.
Pulmonary phenotype of CF can be determined by pulmonary
function tests (e.g. FEV1), bacteriological markers (e.g. age at first
acquisition of Pseudomonas aeruginosa, pulmonary exacerba-
tions requiring IVantibiotics), measurement of structural changes
(e.g. High Resolution Computed Tomography scores), and by
survival. Since CF lung disease is progressive change over time
must be taken into account. Large studies have shown that
patients with Class I, II and III mutations have a steeper rate of
decline in FEV1 than patients who carry one Class IV or V
mutation [97]. However, the variance in FEV1 in patients within
these two groups is considerable and thus prediction of
progression of lung disease in individual patients is not possible
[82]. A patient who is homozygous or compound heterozygous
for class I–III CFTR mutations may present with mild lung
disease. On the other hand, patients who carry at least one class
IV–V mutations may present with severe disease later in life.
Thus, for individual patients, it is impossible to predict reliably the
severity of pulmonary disease based only on CFTR genotype.
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useful predictor of the severity of lung disease in the
individual patient, it should not be used as an
indicator of prognosis.
3.3. CF mutations and other disease manifestations
Other manifestations of CF include gastrointestinal compli-
cations, CF related diabetes, and male infertility.
a. Gastrointestinal complications of CF.
These are mainly meconium ileus (MI), distal intestinal
obstruction syndrome (DIOS), and CF liver disease. Genotype–
phenotype studies of these CF complications are hampered by
small sample sizes, as these complications are seen in 5–20%
of CF patients, and by difficulty in determining a common
definition. This is especially true for CF liver disease, which is
insidious in onset, and with no commonly agreed diagnostic
criteria. Nevertheless, liver disease, MI and DIOS, occur almost
exclusively in patients carrying severe class I–III mutations on
both alleles. However, there is no evidence of a phenotype
relationship with specific gene mutations [98,99]. Modifier
genes seem to play a prominent role in development of MI [100]
and CF-associated liver disease [101].
b. Diabetes
The prevalence of CF-related diabetes (CFRD) increases
with patient age with an overall prevalence of ~ 5%. Around
15–20% of CF adults have CFRD, almost exclusively PI pa-
tients, and thus diabetes is strongly associated with Class I, II
and III mutations [98,102].
c. Male infertility
Obstructive azoospermia is present in the greatest majority of
male patients with CF [103,104], mainly because of congenital
bilateral absence of the vas deferens (CBAVD), but also fol-
lowing other obstructive anatomic abnormalities [105]. CFTR
is very important in the normal development of the vas deferens,
as relatively minor disruption of CFTR function appears to
cause CBAVD. Fertile CF men often carry the 3849 + 10kbC N
T mutation. This correlation is very strong and does allow
prediction of infertility in men with CF who carry mutations
other than 3849+10kbCNT.
Conclusion: There is no correlation between any
specific CFTR mutation and meconium ileus, DIOS,
liver disease, and CF related diabetes. These
manifestations almost never occur in the presence
of a PS mutation.3.4. CFTR mutations in the context of CFTR-related disorders
The best studied CFTR-related disorders are CBAVD and
other forms of obstructive azoospermia, recurrent acute or
chronic pancreatitis, and diffuse bronchiectasis [106–108]. A
prevalence of CFTR mutations higher than expected in the
general population has been reported also in rhinosinusitis,
allergic bronchopulmonary aspergillosis, and sclerosing
cholangitis [44,109–112].
To assess the association between CFTR mutations and these
disorders is often difficult. The prevalence of CFTR mutations
depends on the number of mutations tested (e.g. a limited panel
or full gene sequencing) and on patients' selection criteria.
Besides, these clinical entities may have other non CFTR
etiologies.
a. Congenital bilateral absence of the vas deferens
Obstructive azoospermia, in which CBAVD is the most
common phenotype, is an important cause of infertility and
accounts for 1–5% ofmale infertility. Themolecular basis of this
condition has been investigated by several groups worldwide
with common findings [39,106,107,113–115,116,117]. Shortly
after the discovery of theCFTR gene, Dumur et al. showed that a
large proportion of sterile men with CBAVD carried F508del
[106]. Later studies determined that 80–90% of men with
CBAVD carry at least one and 50–60% have two CFTR
mutations (including the T5 variant). For those men with 2
CFTR mutations, usually one is CF-causing, and the other is a
CFTR-related disorder associated mutation. The F508del mu-
tation is found in 40% of CBAVD patients, followed by the T5
variant in about 35% [39,62,107,115,116,118,119]. R117H was
also frequently reported (about 30%) in these patients [107],
usually in association with the T7 variant [63].
b. Pancreatitis
The evidence of an association of CFTR mutations with
CBAVD led Sharer and Cohn to evaluate the possible role of
CFTR in chronic pancreatitis and to show that the frequency of
a single mutation was 11 fold greater than the expected
frequency in a control population [113,114]. These data were
confirmed later by different groups with a frequency of about
30% of chronic pancreatitis patients carrying one CFTR mu-
tation and 10–15% being compound heterozygotes [120–124].
F508del was the most common severe mutation with the T5
variant, R117H-T7, L206W, D1152H, R1070Q, R347H,
R334W, and 2789+5GNA also seen.
c. Bronchiectasis
CFTR mutations were found in 10–50% of series of patients
with idiopathic bronchiectasis [108,125–130] This variability
may be due to the more heterogeneous nature of bronchiectasis
and may depend upon how exhaustive was the search for other
etiologies. Although the specific CFTR mutations were similar
to those seen in men with CBAVD, fewer patients were found to
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heterozygote, only one mutation is a CF-causing mutation.
Conclusion: A frequency of CFTR mutations
higher than in the general population is found in
individuals with clinical presentations that do not
fulfill the diagnostic criteria of CF, thus called CFTR-
related disorders. CF-causing mutations can be
detected, but not in both CFTR genes.3.5. Modifier genes
Identification of genetic modifiers and determination of their
clinical effect on CF is expected to become an integral part of
assessing disease prognosis, and in some cases may lead to
alternative approaches to therapy. Over 30 studies on CF mod-
ifier genes have been published since 1998. Most of these
studies ascertained very small populations and have not been
replicated. Consequently, there have been a number of diverse
and contradictory conclusions. The current strategy to clarify
this area is to conduct studies on modifiers in large CF patient or
family cohorts, in order to increase statistical power of as-
sociation analyses for various CF clinical traits and specific
covariates.
In spite of some discordance in the most representative
studies results [131–135], a few genes are well-proven to be CF
modifiers (TGFbeta1, MBL2). More research has to be done on
these and other putative CF modifiers, and therefore caution has
to be exercised in interpreting these results. We do not know yet
whether the heritability of CF lung disease variation is due to a
few genes having major effects, or many genes with minor
effects, or some combination of the two. The present level of
knowledge does not allow us to use the results so far achieved in
a clinical context. However it is anticipated that advances in this
area of CF research will provide a basis for prognostic and
therapeutic applications for CF management in the not distant
future.
Conclusion: Modifier candidate gene studies
have so far identified alleles of real but apparently
minor effect. At present time, it does not seem
appropriate to test routinely for modulating muta-
tions/genes, as there is no clear clinical relevance,
nor therapeutic implications.4. Communication of the analysis results
CFTR mutation analysis is among the most common tests in
molecular genetics laboratories. In spite of the frequency of thetest, considerable differences exist in the extent of mutation
testing. The way in which the clinician interprets the report will
have a major impact on the further clinical management of the
tested individual and his family. Therefore it is crucial that the
results are presented in a clear and unambiguous way. Different
entities, including the International Organization for Standardi-
zation [136], the Organization for Economic Co-operation and
Development (OECD) [137], and some scientific societies
[138,139] have drafted guidelines describing the information
that should be included in the molecular genetics laboratory
report to ensure that clinicians and patients receive adequate and
understandable information.
It is important that the information flows from the laboratory
to the clinician, and also from the clinician to the molecular
genetics laboratory. In fact, depending on the indications for
testing, the analysis and the report will have to be adapted as to
include information pertaining specifically to the reasons why
the test was requested, and what its potential clinical utility is.
4.1. From the clinician to the molecular analysis laboratory
The Best Practice Guidelines for Reporting Molecular
Testing Results included in the OECD guidelines for Molecular
Testing [137] states that “as the utility of a genetic test report is
often dependent on the accuracy and adequacy of information
provided to the laboratory, a request for genetic testing should
include all information necessary for the laboratory to perform
appropriate testing and interpret results”.
These general guidelines also apply to CF genetic testing. It is
very important for the molecular genetic laboratory to obtain
information on the ethnicity of the individual to be tested, and
clear indications for testing, before proceeding to the analysis.
This information will help the molecular genetic laboratory
to employ the best possible “targeted” diagnostic protocol.
Mutations which are found in CFTR-related disorders, like
CBAVD or chronic idiopathic pancreatitis, may be different
from those in PI CF. Similarly, somemutations may be rare in the
local population, but relatively frequent in other ethnic groups.
The indications for testing can be reduced to confirming a
clinically proven CF, investigating a suspicion of CF or of a
CFTR-related disorder, and prenatal diagnosis. When testing is
requested to investigate the possibility of CF, it may be useful to
indicate to the laboratory how strong is the evidence so far
collected in favour of CF. Usually, the lower is the mean sweat
chloride concentration, the less likely it is to find any mutation
in the CFTR gene. However, a single CF-causing mutation
found by a standard panel together with CF clinical features are
highly correlated with the presence of a second deleterious
mutation, detectable by more extensive analysis [140].
Conclusion: Integration of clinical and molecular
findings is of paramount importance.Laboratories
should request information about race/ethnicity,
family history, and reason for testing.
Table 7
Check-list for a standard report
✓Laboratory identifiers; (ISO accreditation/certification number if allowed and
applicable)
✓Title, date
✓Name of patient (at least two identifiers; hospital number, sample number, etc)
✓Date of birth, gender
✓Place of birth/ethnic origin
✓Nature of the sample and arrival date
If the DNA is already extracted, name and address of the lab that extracted the
DNA
✓Name and address of the referring physician
✓Indication for testing or question to be answered
✓Test performed, list of mutations tested, sensitivity (mutation detection rate),
methods used (in brief)
✓Result
Formal genotype
Interpretation of result in simple language, including:
Whether the diagnosis has been confirmed
Whether counselling and/or further testing is required
Implications for family members
Need for further testing for additional mutations based on clinical or genetic
motifs
References to scientific publications
✓Signature of lab director, visa/signature of second person (can be electronic)
✓Laboratory's standard phrase concerning reproduction of report and scope of
results.
✓Numbering of pages (1 of 1 …)
Adapted from the recommendations of the Swiss Society of medical genetics
(Best practice guidelines on reporting in molecular genetic diagnostic
laboratories in Switzerland, 2003) and the quality criteria for reporting of the
CF European Network [31].
Table 8
An example of a molecular CF report (modified from a CF network EQA form
http://www.cfnetwork.be/)
XX-0X-200X
Doctor X
Street X
City, Country X
Molecular genetic analysis for cystic fibrosis
Name: Gary BRAUN
Date of birth: 20-06-2006
Gender: Male
Place of birth: Hamburg, Germany
Ethnic origin: Caucasian: mother from Brittany, father from Germany
Reason for referral: Failure to thrive, chronic diarrhea, two episodes
of bronchiolitis and a positive sweat test
Sample received: 3-06-2007
Sample type: DNA
Sample number: MUCO-412
Result Compound heterozygote G551D/R553X
Interpretation
This results shows that Gary Braun is a compound heterozygote for two different
cystic fibrosis mutations. This result confirms the diagnosis of cystic fibrosis.
Comments
Cystic fibrosis is an autosomal recessive disorder and therefore both parents of
the affected child should be carriers of the disease. It is thus suggested that the
parents' DNA should be tested to establish carrier status and origin of each
mutation. Once carrier detection is confirmed, this couple has a 25% risk to
have an affected child in each pregnancy. Prenatal diagnosis is therefore
feasible in this pregnancy and in every subsequent pregnancy of this couple.
Since this is an inherited disease, screening for carrier status of other members
of their families may also be offered.
The parents of the patient and their families should consult with the referring
doctor and a genetic counselor.
Molecular biologist Director
Mutations have been classified according to GenBank Accession Number
NM_000492. Nucleotide 1 has been counted as the first nucleotide of
transcription leading to nucleotide 133 being the first nucleotide of the
translation initiation codon.
The method used: INNO-LiPA CFTR19 and 17+Tn update (reverse dot blot)
Mutations screened for: F508del, I507del, G542X, 1717-1GNA, G551D,
R553X, R560T, Q552X, W1282X, S1251N, 3905insT, N1303K,
CFTRdele2,3, 711+1GNT, 3272-26ANG, 1898+1GNA, I148T⁎, 3199del6,
3120+1GNA, 394delTT, G85E, E60X, 621+1GNT, R117H, 1078delT,
R347P, R334W, 2143delT, 2183AANG, 2184delA, 711+5GNA, R1162X,
3659delC, 3849+10kbCNA, A455E, T5, T7, T9 (⁎I148T is a neutral
polymorphism and does not cause CF disease)
The mutation detection rate is about 90% for the North European Caucasian
population and ≤70% for South European Caucasians.
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A complete written report should always conclude the testing
[137]. The person tested should also receive either a copy of the
original laboratory report, or the report will be included in a
more comprehensive report of the genetic counselling session or
of the hospitalization.
Test results should be reported using the terminology de-
scribed above: disease-causing mutations, mutations of uncer-
tain clinical relevance, and mutations of unknown clinical
relevance. Polymorphisms or mutations with no clinical re-
levance may be misinterpreted by the clinician or the patient,
and should not be mentioned in the report. A statement to this
effect should be placed in every report.
The clinical relevance and the consequences of the
molecular findings for the individual, and for his/her family
should be explained. The information provided should be clear
and concise, as too much information may confuse the exact
meaning of the result. Referral to a physician belonging to a CF
centre or with experience in the care of CF and/or to a genetic
counsellor for additional information as well as for further
diagnostic work up may be more appropriate.
Laboratories should provide estimated clinical sensitivity
and specificity. Clinical sensitivity is defined as the proportion
of individuals who have CF and who also have a positive CF
test with two identifiable CF-causing mutations. Currently, mostlaboratories will merely rely on published reports. For example,
the panel of 23 mutations proposed by the ACMG will identify
about 88% of carriers in Caucasians. Thus, about 77% (88% ×
88%) of Caucasians with CF (or the same proportion of car-
rier couples) will have a positive test result (two mutations
identified). In case one or no mutation is identified in a CF
patient, laboratories should comment on the feasibility of
192 C. Castellani et al. / Journal of Cystic Fibrosis 7 (2008) 179–196further testing. Laboratories should also be able to provide
estimated clinical sensitivities for other defined racial/ethnic
groups that may be tested. Clinical specificity can be defined as
the proportion of negative test results among individuals who do
not have CF. Analytical error or variable expressivity of certain
mutations can reduce the clinical specificity of the test. Al-
though the clinical expression of most of the commonly tested
mutations is known to be highly consistent with a classic
CF phenotype, there may be some exceptions. For example,
the R117H mutation may produce a quite variable clinical
phenotype.
Large intragenic CFTR gene deletions and benign variants
can lead to incorrect assignment of homozygosity when a
mutation is present at the same site on the second allele.
Parental testing to confirm homozygosity is always
recommended.
For neonatal screening results, the report will be made
available according to the procedures established regionally or
nationally for neonatal screening.
Conclusion: A standard molecular analysis
laboratory report should be provided for all diag-
nostic analysis for CF. A check-list for a standard
molecular analysis laboratory report and an example
of a typical report are shown in Tables 7 and 8.4.3. Mutation nomenclature
Mutation nomenclature needs to be accurate and unambig-
uous. However, the effort of producing a reliable nomenclature
has led, in recent years, to wide disparities in the naming of
DNA sequence variants. The traditional mutation nomencla-
ture is currently used in the vast majority of research papers,
and in the CFGAC Mutation Database. More recently, a com-
pletely different nomenclature has been recommended by the
Human Genome Variation Society (HGVS) (Human Genome
Variation Society. Nomenclature for the description of
sequence variations) [141]. HGVS is an international body
for defining gene variation nomenclature under the umbrella of
the Human Genome Organization (HUGO) and the Interna-
tional Federation of Human Genetics Societies (IFHGS).
HGVS nomenclature is still evolving. The simultaneous use
of ‘traditional’ versus ‘HGVS’ nomenclature is a potential
source of confusion, both in the laboratory and the clinical
setting. In this regard, the Cystic Fibrosis European Network
has produced the following statement: “It is recommended that
the symbol Δ is not used, but F508del and I507del are used
instead. At present, we advise using the mutation names of the
routinely and widely used CFTR mutation database [4]. If
HGVS nomenclature is used, reference should be made to the
‘traditional’ mutation names, to avoid confusion for the refer-
ring clinician. HGVS nomenclature can be included in a
footnote, if a laboratory considers it essential.” [34]. Presently,the parallel HGVS nomenclature will be incorporated into the
CFGAC Mutation Database.
Conclusion: Many frequently observed muta-
tions have historical names which do not comply
with the HGVS recommendations. Currently most
clinicians are familiar with the historical names.
Therefore, at present adoption of the standard-
ised system will inevitable result in confusion. It
is recommended that laboratory reports include
HGVS nomenclature in addition to the traditional
name.
4.4. Carrier testing and carrier screening
CF carrier testing is advised in relatives of a person with CF
or in the partner of a CF carrier who is planning to have children
[142]. Carrier testing of children should be deferred until the
child is old enough to make an informed decision about the
implications of genetic analysis [143]. In several countries,
population carrier testing is also offered to individuals or
couples with no family history of CF. For over the counter or
direct to consumer testing, pre-test information should be given
to the individual being tested and genetic counselling should be
made available to him/her to review the exact meaning of the
result. In this regard, more information about CF testing should
be made available to the general public to prepare them to better
understand the relevance and impact of testing. Software
programs that teach people about the potential value and
limitations of the CF carrier testing may offer some useful
insights. Population screening for CF carriers should conform to
the same basic quality principles as those which apply for the
testing of individuals.
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Allele: alternative forms of a gene at a given locus.
CF-causing mutation: a DNA sequence alteration causing CF, if in transwith
another CF-causing mutation.
CFTR-related disorders: clinical entities associated with CFTR mutations,
but where a diagnosis of CF cannot be made by the current standard diagnostic
criteria.
Complex allele: more than two functional DNA alterations on a single allele.
Exon: region of DNA within a gene that is transcribed to the final mRNA and
that usually contains coding information.
Frameshift mutation: a mutation involving a deletion or insertion that is not
an exact multiple of three base pairs, which changes the reading frame of the
gene.
Gene scanning: analysis of DNA by indirect means, as opposed to direct
identification by sequencing, aimed at identifying sequence alterations.
Gene sequencing: process of recording the exact sequence of nucleotides in a
given gene fragment.
In cis: two mutations on the same parental CFTR gene.
In trans: two mutations on different parental CFTR genes.
Haplotype: a series of alleles found at near loci on the same chromosome.
Intron: a non-coding sequence of DNA that is initially copied into RNA but is
cut out of the final RNA transcript.
Missense mutation: a single DNA base substitution resulting in a codon
specifying a different amino acid.
Modifier gene: a gene that affects the phenotypic expression of another gene.
Mutation: an alteration in DNA sequence, whose molecular and clinical
consequences are not established, and could range from having no consequences
to deleterious or beneficial.
Nonsense mutation: a single DNA base substitution resulting in a stop
(termination) codon.
Polymorphism: in population genetics, a DNA sequence alteration which has
a frequency of at least 1% in the general population. In medical genetics, the
term polymorphism is often incorrectly used as a synonym for non disease-
causing variant.
Promoter: a DNA sequence located upstream the coding sequence of the
gene, which contains information for temporal and spatial activation of the gene.
Segregation analysis: a procedure for investigating the pattern of inheritance
of a character within a family.
Splicing: removal of introns in the generation of mature RNA.
Uniparental disomy: situation in which both copies of a chromosome pair
have originated from one parent.
